South San Francisco, CA, United States of America

Grace Jungeun Lee

This inventor holds 1 USPTO granted patent. Top assignee: Sutro Biopharma, Inc.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Grace Jungeun Lee: Innovator in Antibody Research

Introduction

Grace Jungeun Lee is a prominent inventor based in South San Francisco, California. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibody therapies. Her work focuses on advancing medical treatments through her research and inventions.

Latest Patents

Grace Jungeun Lee holds a patent titled "Anti-Tissue Factor Antibodies and Antibody Conjugates, Compositions Comprising Anti-Tissue Factor Antibodies or Antibody Conjugates, and Methods of Making and Using Anti-Tissue Factor Antibodies and Antibody Conjugates." This patent represents her groundbreaking work in creating novel therapeutic agents that target tissue factor, which plays a crucial role in various diseases.

Career Highlights

Currently, Grace is employed at Sutro Biopharma, Inc., where she continues to push the boundaries of antibody research. Her dedication to innovation has led to the development of new therapeutic strategies that have the potential to improve patient outcomes.

Collaborations

Grace has collaborated with talented individuals in her field, including Junhao Yang and Krishna Bajjuri. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Grace Jungeun Lee is a remarkable inventor whose work in antibody research is paving the way for new medical advancements. Her contributions to the field are invaluable, and her innovative spirit continues to inspire others in the biopharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…